Senate panel to vote on FDA nominee next week

Senate panel to vote on FDA nominee next week
© Getty Images

The Senate health committee will vote next Tuesday on President Obama’s nominee to be commissioner of the Food and Drug Administration. 

The nominee, Dr. Robert Califf, is a cardiologist and longtime Duke University researcher who joined the FDA as a deputy commissioner in February. He has received praise from Chairman Lamar AlexanderLamar AlexanderLawmakers reintroduce online sales tax bills Overnight Healthcare: New GOP health bill on life support | ObamaCare insurer threatens to leave over subsidies Trump's FDA nominee clears key Senate committee MORE (R-Tenn.) and is expected to have relatively smooth sailing. 

He has received blowback from the left, though, over concerns that his ties with drug companies are too tight. Califf was a consultant for drug companies and has done research funded by the industry. 

In October, Sen. Bernie SandersBernie SandersNRA head: Sanders 'a political predator' What would Bernie say to Wall Street for 0K? Sanders warns of possible nuclear war with North Korea MORE (I-Vt.) announced he would oppose the nomination. “We need a new leader at the FDA who is prepared to stand up to the pharmaceutical companies and work to substantially lower drug prices,” Sanders said in a statement. “Unfortunately, I have come to the conclusion that Dr. Califf is not that person.”

At a confirmation hearing in November, Califf defended his research while at Duke. “Yes, the industry funds the studies,” he said. “But we have an independent voice guaranteed by a contract.”

The nomination comes at a time when the FDA is in the spotlight over the issue of high drug prices. 

Alexander’s committee is pivoting early this year to try to finish up work on a bipartisan medical innovation bill, a companion to the House-passed 21st Century Cures measure, that seeks to speed up the FDA’s approval process for new drugs. Some Republicans portray that effort as a way to increase competition and lower prices by getting more drugs to market. 

For Democrats, the innovation bill is not enough, and they also want more far-reaching proposals like allowing Medicare to negotiate drug prices down.